Adverse effects of antiretroviral therapy (Q34071132)

30 July 2017

1 reference

title

Adverse effects of antiretroviral therapy (English)

1 reference

30 July 2017

anti-retroviral agent

0 references

author name string

A Carr

series ordinal

1

1 reference

PubMed ID

11052597

30 July 2017

D A Cooper

series ordinal

2

1 reference

PubMed ID

11052597

30 July 2017

language of work or name

English

0 references

publication date

1 October 2000

1 reference

30 July 2017

1 reference

30 July 2017

356

1 reference

30 July 2017

1423-1430

1 reference

30 July 2017

9239

1 reference

Latent infection of CD4+ T cells provides a mechanism for lifelong persistence of HIV-1, even in patients on effective combination therapy

30 July 2017

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2800%2902854-3

7 January 2021

Recovery of replication-competent HIV despite prolonged suppression of plasma viremia

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2800%2902854-3

7 January 2021

Mitochondrial toxicity of antiviral drugs

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2800%2902854-3

7 January 2021

Adverse effects of reverse transcriptase inhibitors: mitochondrial toxicity as common pathway

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2800%2902854-3

7 January 2021

Zidovudine-induced mitochondrial myopathy is associated with muscle carnitine deficiency and lipid storage

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2800%2902854-3

7 January 2021

Fulminant hepatic failure associated with 2',3'-dideoxyinosine (ddI)

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2800%2902854-3

7 January 2021

A syndrome of lipoatrophy, lactic acidaemia and liver dysfunction associated with HIV nucleoside analogue therapy: contribution to protease inhibitor-related lipodystrophy syndrome.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2800%2902854-3

7 January 2021

Hepatic failure and lactic acidosis due to fialuridine (FIAU), an investigational nucleoside analogue for chronic hepatitis B.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2800%2902854-3

7 January 2021

Rates and risk factors for adverse events associated with didanosine in the expanded access program

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2800%2902854-3

7 January 2021

Peripheral neuropathy with nucleoside antiretrovirals: risk factors, incidence and management

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2800%2902854-3

7 January 2021

Lactic acidosis in critical illness

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2800%2902854-3

7 January 2021

The treatment of mitochondrial myopathies and encephalomyopathies

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2800%2902854-3

7 January 2021

Severe adverse cutaneous reactions to drugs

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2800%2902854-3

7 January 2021

Cutaneous disease and drug reactions in HIV infection

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2800%2902854-3

7 January 2021

Focal mycobacterial lymphadenitis following initiation of protease-inhibitor therapy in patients with advanced HIV-1 disease.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2800%2902854-3

7 January 2021

A syndrome of peripheral lipodystrophy, hyperlipidaemia and insulin resistance in patients receiving HIV protease inhibitors

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2800%2902854-3

7 January 2021

"Buffalo hump" in men with HIV-1 infection.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2800%2902854-3

7 January 2021

Redistribution of body fat in HIV-infected women undergoing combined antiretroviral therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2800%2902854-3

7 January 2021

Diagnosis, prediction, and natural course of HIV-1 protease-inhibitor-associated lipodystrophy, hyperlipidaemia, and diabetes mellitus: a cohort study

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2800%2902854-3

7 January 2021

A syndrome of peripheral fat wasting (lipodystrophy) in patients receiving long-term nucleoside analogue therapy.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2800%2902854-3

7 January 2021

Protease inhibitor-associated hyperglycaemia

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2800%2902854-3

7 January 2021

Treatment with protease inhibitors associated with peripheral insulin resistance and impaired oral glucose tolerance in HIV-1-infected patients.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2800%2902854-3

7 January 2021

Pathogenesis of HIV-1-protease inhibitor-associated peripheral lipodystrophy, hyperlipidaemia, and insulin resistance.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2800%2902854-3

7 January 2021

Inhibition of adipocyte differentiation by HIV protease inhibitors

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2800%2902854-3

7 January 2021

Stimulation of vitamin A(1) acid signaling by the HIV protease inhibitor indinavir

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2800%2902854-3

7 January 2021

Mitochondrial toxicity induced by nucleoside-analogue reverse-transcriptase inhibitors is a key factor in the pathogenesis of antiretroviral-therapy-related lipodystrophy

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2800%2902854-3

7 January 2021

Lipodystrophy following antiretroviral therapy of primary HIV infection

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2800%2902854-3

7 January 2021

Clinical progression and virological failure on highly active antiretroviral therapy in HIV-1 patients: a prospective cohort study

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2800%2902854-3

7 January 2021

Highly active antiretroviral therapy in a large urban clinic: risk factors for virologic failure and adverse drug reactions

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2800%2902854-3

7 January 2021

Severe premature coronary artery disease with protease inhibitors

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2800%2902854-3

7 January 2021

Myocardial infarction in HIV-infected men receiving protease inhibitors

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2800%2902854-3

7 January 2021

A pilot study of exercise training to reduce trunk fat in adults with HIV-associated fat redistribution

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2800%2902854-3

7 January 2021

Atorvastatin and gemfibrozil for protease-inhibitor-related lipid abnormalities

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2800%2902854-3

7 January 2021

Reversal of protease inhibitor-related visceral abdominal fat accumulation with recombinant human growth hormone

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2800%2902854-3

7 January 2021

Liposuction for protease-inhibitor-associated lipodystrophy

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2800%2902854-3

7 January 2021

Reversion of metabolic abnormalities after switching from HIV-1 protease inhibitors to nevirapine.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2800%2902854-3

7 January 2021

The effects of discontinuing stavudine therapy on clinical and metabolic abnormalities in patients suffering from lipodystrophy

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2800%2902854-3

7 January 2021

Hydroxyurea and HIV: 5 years later--from antiviral to immune-modulating effects

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2800%2902854-3

7 January 2021

A placebo-controlled trial of didanosine plus stavudine, with and without hydroxyurea, for HIV infection. The Swiss HIV Cohort Study

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2800%2902854-3

7 January 2021

Changes in renal function associated with indinavir

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2800%2902854-3

7 January 2021

Variation in incidence of indinavir-associated nephrolithiasis among HIV-positive patients

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2800%2902854-3

7 January 2021

Influence of environmental temperature on incidence of indinavir-related nephrolithiasis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2800%2902854-3

7 January 2021

Paronychia and pyogenic granuloma of the great toes in patients treated with indinavir

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2800%2902854-3

7 January 2021

Alopecia Associated with Indinavir Therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2800%2902854-3

7 January 2021

A short-term study of the safety, pharmacokinetics, and efficacy of ritonavir, an inhibitor of HIV-1 protease. European-Australian Collaborative Ritonavir Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2800%2902854-3

7 January 2021

A preliminary study of ritonavir, an inhibitor of HIV-1 protease, to treat HIV-1 infection

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2800%2902854-3

7 January 2021

A preliminary evaluation of nelfinavir mesylate, an inhibitor of human immunodeficiency virus (HIV)-1 protease, to treat HIV infection

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2800%2902854-3

7 January 2021

Acute hepatitis in a patient treated with saquinavir and ritonavir: absence of cross-toxicity with indinavir

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2800%2902854-3

7 January 2021

Restoration of immunity to chronic hepatitis B infection in HIV-infected patient on protease inhibitor

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2800%2902854-3

7 January 2021

The steady-state plasma pharmacokinetics of indinavir alone and in combination with a low dose of ritonavir in twice daily dosing regimens in HIV-1-infected individuals

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2800%2902854-3

7 January 2021

Persistent mitochondrial dysfunction and perinatal exposure to antiretroviral nucleoside analogues

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2800%2902854-3

7 January 2021

Safety of the maternal-infant zidovudine regimen utilized in the Pediatric AIDS Clinical Trial Group 076 Study

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2800%2902854-3

7 January 2021

Nevirapine induced opiate withdrawal among injection drug users with HIV infection receiving methadone

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2800%2902854-3

7 January 2021

Increased bleeding in HIV-positive haemophiliacs treated with antiretroviral protease inhibitors

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2800%2902854-3

7 January 2021

Zidovudine toxicity in uninfected healthcare workers

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2800%2902854-3

7 January 2021

Anti-human immunodeficiency virus (HIV) activity, safety, and pharmacokinetics of adefovir dipivoxil (9-[2-(bis-pivaloyloxymethyl)-phosphonylmethoxyethyl]adenine) in HIV-infected patients

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2800%2902854-3

7 January 2021

Phase I study of 2′-3′-dideoxyinosine administered orally twice daily to patients with AIDS or AIDS-related complex and hematologic intolerance to zidovudine

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2800%2902854-3

7 January 2021

A trial comparing nucleoside monotherapy with combination therapy in HIV-infected adults with CD4 cell counts from 200 to 500 per cubic millimeter. AIDS Clinical Trials Group Study 175 Study Team

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2800%2902854-3

7 January 2021

Riboflavine and severe lactic acidosis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2800%2902854-3

7 January 2021

Protective actions of L-carnitine and acetyl-L-carnitine on the neurotoxicity evoked by mitochondrial uncoupling or inhibitors

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2800%2902854-3

7 January 2021

Clinical and laboratory markers of hypersensitivity to trimethoprim-sulfamethoxazole in patients with Pneumocystis carinii pneumonia and AIDS.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2800%2902854-3

7 January 2021

Corticosteroids prevent early deterioration in patients with moderately severe Pneumocystis carinii pneumonia and the acquired immunodeficiency syndrome (AIDS)

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2800%2902854-3

7 January 2021

Safety profile of nevirapine, a nonnucleoside reverse transcriptase inhibitor for the treatment of human immunodeficiency virus infection

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2800%2902854-3

7 January 2021

Vascular complications associated with use of HIV protease inhibitors

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2800%2902854-3

7 January 2021

Intrapartum and neonatal single-dose nevirapine compared with zidovudine for prevention of mother-to-child transmission of HIV-1 in Kampala, Uganda: HIVNET 012 randomised trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2800%2902854-3

7 January 2021

Effects of hydroxyurea administration on the body weight, body composition and exercise performance of patients with sickle-cell anaemia.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2800%2902854-3

7 January 2021

The value of patient-reported adherence to antiretroviral therapy in predicting virologic and immunologic response. California Collaborative Treatment Group

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2800%2902854-3

7 January 2021

Benign symmetric lipomatosis associated with protease inhibitors

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2800%2902854-3

7 January 2021

Fatal interaction between ritonavir and MDMA

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2800%2902854-3

7 January 2021

Sudden cardiac death in a patient on 2 years of highly active antiretroviral treatment: a case report

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2800%2902854-3

7 January 2021

Drug points: severe ergotism associated with interaction between ritonavir and ergotamine

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2800%2902854-3

7 January 2021

Visceral abdominal-fat accumulation associated with use of indinavir

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2800%2902854-3

7 January 2021

Ritonavir, triglycerides, and pancreatitis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2800%2902854-3

7 January 2021

Development of cervical fat pads following therapy with human immunodeficiency virus type 1 protease inhibitors.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2800%2902854-3

7 January 2021

Indinavir-associated lipodystrophy.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2800%2902854-3

7 January 2021

3'-Azidothymidine (zidovudine) inhibits glycosylation and dramatically alters glycosphingolipid synthesis in whole cells at clinically relevant concentrations

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2800%2902854-3

7 January 2021

Insulin resistance in HIV protease inhibitor-associated diabetes

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2800%2902854-3

7 January 2021

HIV and AIDS. Gap between biology and reality in AIDS

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2800%2902854-3

7 January 2021

The case for more cautious, patient-focused antiretroviral therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2800%2902854-3

7 January 2021

10.1016/S0140-6736(00)02854-3

Identifiers

DOI

1 reference

30 July 2017

1 reference

PubMed ID

11052597